Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Saturday, 13 November 2010
40 deaths linked to child vaccines - MHRA confirm - source Sunday Times
40 deaths linked to child vaccines over seven years
Childhood vaccinations are suspected to have left two children with
brain injuries and caused 1,500 other neurological reactions
Sarah-Kate Templeton, Health Editor
Published: 24 October 2010
Forty children are suspected to have died as a result of receiving
routine vaccines in the past seven years.
Childhood vaccinations are also suspected of having left two young
children with brain injuries and caused more than 1,500 other
neurological reactions, including 11 cases of inflammation of the
brain, 13 cases of epilepsy and a coma.
The data, disclosed by the Medicines and Healthcare products
Regulatory Authority (MHRA) following a request by The Sunday Times
under the Freedom of Information Act, shows that, since 2003, there
have been more than 2,100 serious adverse reactions to childhood
vaccines, some of which were life-threatening.
Fifteen injections are given routinely to young children as part of
the governments vaccination programme. They offer protection against
diseases such as polio, diphtheria, mumps and measles.
The MHRA says the deaths and neurological reactions should be seen in
the context of the 90m doses of childhood vaccines which have been
given since 2003.
Details of the suspected deaths and neurological problems have been
released just two months after a legal ruling forced the government to
accept that its vaccination programme had left a baby severely brain
damaged.
Thirteen years after first refusing to acknowledge that Robert
Fletcher, now 18, had been left severely brain damaged by the MMR
vaccine for measles, mumps and rubella, the government was forced to
pay him compensation.
Roberts mother, Jackie, who founded Jabs, a support group for
families with vaccine-damaged children, said: It is generally
accepted within the medical profession that only about 10% of
suspected adverse reactions get put forward in the correct way. It is
accepted by the Department of Health that the full scale of the
problem is far greater than these statistics show.
Jake Dukes, 18, from Weymouth, Dorset, was left severely brain damaged
by the whooping cough vaccine, which he received when he was two
months old. He has the mental age of a toddler, is incontinent and
uses a wheelchair. He was awarded £91,500 under the governments
vaccine damage payment scheme.
The family of George Fisher are convinced that the MMR vaccine
contributed to the death of their 18-month-old son. He died 10 days
after being inoculated in January 2006.
His mother, Sarah, a hotel receptionist from Cheltenham,
Gloucestershire, believes that an existing illness made him
susceptible to an adverse reaction to the vaccine. Four months before
receiving the jab, George had suffered a fit brought on by a high
fever. Sarah said: George had had a bad virus. He had been very ill
and had suffered a convulsion due to his high temperature. I dont
think it was just the MMR, but I think it was a factor in his death.
Friday, 12 November 2010
Mark Harvey's firm takes legal aid funding then drops depression drug case !!!!
Mark Harvey's firm takes legal aid funding then drops depression drug case !!!!
British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions,believing that the cases would be impossible to prove.
Copyright 2004 Times Newspapers Ltd
Roaccutane.Campaigners against the drug believe that the exercise would demonstrate a strong link between use of the drug and suicide.However, a British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions, believing that the cases would be impossible to prove."About 80 or 90 claimants came forward but we had to report that we did not think the claims could be won," said Mark Harvey, now a partner in Hugh James, the solicitors in Cardiff. "You have to beable to link depression to the drug and it would be difficult to prove that it might not have arisen anyway and to eliminate other causes. Isn't depression a side effect of puberty or acne in any event?
It is going to be difficult to get the Legal Aid Board to reopen this."
Copyright 2004 Times Newspapers Ltd
British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions,believing that the cases would be impossible to prove.
Copyright 2004 Times Newspapers Ltd
Roaccutane.Campaigners against the drug believe that the exercise would demonstrate a strong link between use of the drug and suicide.However, a British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions, believing that the cases would be impossible to prove."About 80 or 90 claimants came forward but we had to report that we did not think the claims could be won," said Mark Harvey, now a partner in Hugh James, the solicitors in Cardiff. "You have to beable to link depression to the drug and it would be difficult to prove that it might not have arisen anyway and to eliminate other causes. Isn't depression a side effect of puberty or acne in any event?
It is going to be difficult to get the Legal Aid Board to reopen this."
Copyright 2004 Times Newspapers Ltd
Acne drug not found to increase suicide risk
People being treated for severe acne should have their mental health closely monitored, a study reports.
http://www.bbc.co.uk/news/health-11734080
But a popular acne drug was not found to increase the risk of suicide, despite previous findings.
The study of 5,700 people, in the British Medical Journal, was carried out at the Karolinska Institute, Sweden between 1980 and 2001.
Acne can have serious psychological effects, say experts.
Severe acne sufferers are commonly prescribed a drug called isotretinoin, also known as Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan.
It has been used since the 1980s to treat severe acne if a course of antibiotics does not prove effective.
But there have been reports linking isotretinoin to depression and suicidal behaviour.
So Dr Anders Sundstrom and his research team from Sweden studied suicide attempts before, during and after treatment with this drug for severe acne.
Continue reading the main story
“
Start Quote
Acne can have significant psychological effects .”
End Quote
Dr Sarah Bailey
University of Bath
They found that 128 of the 5,700 patients investigated who were taking the drug were admitted to hospital for attempted suicide.
The risk of suicide was highest within six months of ending treatment - but the researchers say this is most likely to be because patients whose acne improved following treatment were distraught if there was no improvement in their social life, rather than anything to do with the treatment itself.
They stress that attempted suicide was a rare event - the figures suggest just one person out of every 2,300 individuals taking isotretinoin will make a first suicide attempt.
Monitor patients
Dr Sundstrom said of his findings: "The underlying condition of acne is a more important factor for suicide attempts. We are not certain the drug adds anything."
Writing in an editorial in the BMJ, Australian acne experts John Sullivan and Parker Magin say that the Swedish research is important given the complexity of the issue.
"It is difficult to tease out the relation between mental health and isotretinoin because acne itself is associated with psychiatric morbidity, including depression."
They also say that the study shows GPs must closely monitor acne patients on isotretinoin.
"During and after treatment with isotretinoin (perhaps, especially, unsuccessful treatment), patients should be carefully monitored for depression and suicidal thoughts."
Dr Sarah Bailey, lecturer in the Department of Pharmacy and Pharmacology at the University of Bath, said: "This is an important paper that strengthens the view that acne itself can have significant psychological effects and that there is a low risk of suicide for some acne patients.
"However, the controversial issue of increased suicide risk with isotretinoin use is not resolved by this paper, which the authors themselves acknowledge.
"Perhaps their most interesting and novel finding is that the risk of suicide is increased AFTER treatment has stopped and therefore it is essential to continue to monitor patients carefully."
http://www.bbc.co.uk/news/health-11734080
But a popular acne drug was not found to increase the risk of suicide, despite previous findings.
The study of 5,700 people, in the British Medical Journal, was carried out at the Karolinska Institute, Sweden between 1980 and 2001.
Acne can have serious psychological effects, say experts.
Severe acne sufferers are commonly prescribed a drug called isotretinoin, also known as Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan.
It has been used since the 1980s to treat severe acne if a course of antibiotics does not prove effective.
But there have been reports linking isotretinoin to depression and suicidal behaviour.
So Dr Anders Sundstrom and his research team from Sweden studied suicide attempts before, during and after treatment with this drug for severe acne.
Continue reading the main story
“
Start Quote
Acne can have significant psychological effects .”
End Quote
Dr Sarah Bailey
University of Bath
They found that 128 of the 5,700 patients investigated who were taking the drug were admitted to hospital for attempted suicide.
The risk of suicide was highest within six months of ending treatment - but the researchers say this is most likely to be because patients whose acne improved following treatment were distraught if there was no improvement in their social life, rather than anything to do with the treatment itself.
They stress that attempted suicide was a rare event - the figures suggest just one person out of every 2,300 individuals taking isotretinoin will make a first suicide attempt.
Monitor patients
Dr Sundstrom said of his findings: "The underlying condition of acne is a more important factor for suicide attempts. We are not certain the drug adds anything."
Writing in an editorial in the BMJ, Australian acne experts John Sullivan and Parker Magin say that the Swedish research is important given the complexity of the issue.
"It is difficult to tease out the relation between mental health and isotretinoin because acne itself is associated with psychiatric morbidity, including depression."
They also say that the study shows GPs must closely monitor acne patients on isotretinoin.
"During and after treatment with isotretinoin (perhaps, especially, unsuccessful treatment), patients should be carefully monitored for depression and suicidal thoughts."
Dr Sarah Bailey, lecturer in the Department of Pharmacy and Pharmacology at the University of Bath, said: "This is an important paper that strengthens the view that acne itself can have significant psychological effects and that there is a low risk of suicide for some acne patients.
"However, the controversial issue of increased suicide risk with isotretinoin use is not resolved by this paper, which the authors themselves acknowledge.
"Perhaps their most interesting and novel finding is that the risk of suicide is increased AFTER treatment has stopped and therefore it is essential to continue to monitor patients carefully."
Thursday, 11 November 2010
Good Relations & Hugh James are carefully controlling Seroxat media
Litigation and individual members’ cases should not be discussed at support meetings.
Contacting the media. Please do not encourage your members to contact the media. The Group, with Hugh James and Good Relations, are co-ordinating a carefully controlled media approach. If a member of the group asks for your advice on approaching the media, please put them in touch with the committee.
Medical advice. Be careful not to give, or appear to give, medical advice.
Please do not contact any organisation or individual on behalf of the Seroxat Users Group unless you have discussed this with the committee first.
Please do not claim to represent the views of the Seroxat Users Group.
Handling the press and making statements Unless you are promoting the launch of your group, please do not contact the press. Before contacting the press about your group, it is important you contact John Wilkinson of Good Relations. His telephone number is 029 2034 4888 and his email address is jwilkinson@goodrelations.co.uk. Please advise Hugh James and the committee of your contact with the press so that they can be prepared for enquiries.
If you are contacted by a member of the press on any topic, it is important that you do not make any statement, provide information or take part in an interview without talking to John Wilkinson. Please take the journalist’s name, organisation and contact details and promise to get back to them. Do not feel pressurised to answer questions or respond immediately.
http://www.seroxatusergroup.org.uk/Documents/regionalsupport.doc
Seroxat Janice Simmons knew nothing about medical background of Seroxat issue
Andrew Isaac said Date: 2003/06/30 Mon AM 08:30:08
I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
Online donations have been drawn on by Sarah V (venn) - a large sum (from Best Magazine) was used > to pay for the website
Online donations have been drawn on by Sarah V and then Paid to myself > to cover costs I have incurred re: the group. Things like train tickets > for the protest, postage and a large sum (from Best Magazine) was used > to pay for the website. Everything is above board and documented. > > I agree that it must be very frustrating that you cannot access the > website and would also agree that from a member's perspective the delay > in getting the bank account open can be seen as unacceptable. Please > remember that we are doing this in our spare time and work very hard.
http://www.hardwicke.co.uk/barrister-profile/_/14/sarah-venn
http://bobfiddaman.blogspot.com/2010/11/charity-co-ordinator-dr-andrew-isaac.html
http://www.hardwicke.co.uk/barrister-profile/_/14/sarah-venn
http://bobfiddaman.blogspot.com/2010/11/charity-co-ordinator-dr-andrew-isaac.html
"charity co-ordinator" Dr Andrew Isaac replies - confirms seroxatUSERgroup had no bank account
> From: "Andrew Isaac" andrew@seroxatusergroup.org.uk> > Date: 2003/06/30 Mon AM 08:30:08 GMT > To: red.ordead@ntlworld.com> > Subject: RE: urgent seroxat user group > > Dear Claire, > > Many thanks for your email and I will try and answer your questions as > best I can. The Bank account was due to be opened in January this year > but, because the committee members live so far apart it meant that every > one had to send their ID to their branch so that it could then be > forwarded to the branch we wanted to open it at - my local branch! There > was an error on the form that Janice Simmons had to correct, so the form > was sent to her. > > Janice was in the process of moving and caring for her husband John who > is going through the hell of withdrawal. This lost/cost us 3mnths where > it just wasn't possible for her to get to the bank. Since then the > problem has been when Janice has gone to her branch they say they cannot > open the account and it looks as though we will all have to be in the > same place at the same time - this will be on the 10th July - and the > account will be opened then. > > Online donations have been drawn on by Sarah V and then Paid to myself > to cover costs I have incurred re: the group. Things like train tickets > for the protest, postage and a large sum (from Best Magazine) was used > to pay for the website. Everything is above board and documented. > > I agree that it must be very frustrating that you cannot access the > website and would also agree that from a member's perspective the delay > in getting the bank account open can be seen as unacceptable. Please > remember that we are doing this in our spare time and work very hard. I > realise form the perspective of people who use the message board it > looks as though Sarah does everything but that isn't the case. > > Sarah definitely had the most public exposure but we all have > contributed roughly equal amount to the running of the group. I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
Wednesday, 10 November 2010
Sarah Venn advises me there is no bank account for me to pay funds into - Claire Doherty > Red.ordead@ntlworld.com
-----Original Message----- > From: red.ordead@ntlworld.com [mailto:red.ordead@ntlworld.com] > Sent: 30 June 2003 01:12 > To: andrew@seroxatusergroup.org.uk; ABennett@bluepumpkin.com; > trish@canutewalk.fsnet.co.uk; sarah@seroxatusergroup.org.uk; > lydia@hastingsdiving.com; charliegreig@hotmail.com > Subject: urgent seroxat user group > > Dear committee member, > I would like to donate money to the group. > Sarah Venn advises me there is no bank account for me to pay funds into > Why? > What is happening to the online donations? > Why in six months has a bank account not been opened? > It is vital to the running of the group > I have grave concerns about the groups management > Also the site has now exceeded its bandwidth so members will not be able > to access it. > > This bank account needs to be open, otherwise how can we make donations > and how can the group continue, with such limited funding. This is a > grave worry to me as the seroxat user group is my life line and many > other members too. > I can honestly say without it I wouldnt be here. > Please can you get this sorted > I look forward to your response > > Yours hopefully > Claire Doherty > Red.ordead@ntlworld.com > >
seroxatUSERgroup who lied when they claimed to be a charity - via "wayback machine"
http://web.archive.org/web/20050427235427/www.seroxatusergroup.org.uk/who_we_are.htm
Who We Are
Janice Simmons - Charity Co-Ordinator
"I am the wife of a long term Seroxat user, and therefore I'm particularly interested in those of you who have partners, family and friends that need help in understanding the problems of taking Seroxat. I know how much it can affect all members of a family, as well as the user."
Email: janice@seroxatusergroup.org.uk
Andrew Isaac - Charity Co-Ordinator
"I took Seroxat for approximately four years and despite a protracted withdrawal, I have now successfully withdrawn from the drug. I am 30 years old and am studying medicine."
Email: andrew@seroxatusergroup.org.uk
Can You Help?
We are a self funding, non profit making organisation, and hope that you may be able to make a donation towards funding our operational costs.
Who We Are
Janice Simmons - Charity Co-Ordinator
"I am the wife of a long term Seroxat user, and therefore I'm particularly interested in those of you who have partners, family and friends that need help in understanding the problems of taking Seroxat. I know how much it can affect all members of a family, as well as the user."
Email: janice@seroxatusergroup.org.uk
Andrew Isaac - Charity Co-Ordinator
"I took Seroxat for approximately four years and despite a protracted withdrawal, I have now successfully withdrawn from the drug. I am 30 years old and am studying medicine."
Email: andrew@seroxatusergroup.org.uk
Can You Help?
We are a self funding, non profit making organisation, and hope that you may be able to make a donation towards funding our operational costs.
Glaxo's Wellbutrin Class Action Lawsuit Certification Denied
Wellbutrin Class Action Lawsuit Certification Denied
Published: October 26th, 2010 • No Comments
http://www.aboutlawsuits.com/wellbutrin-class-action-lawsuit-denied-13699/
A federal judge has refused to grant certification for a Wellbutrin class action lawsuit filed on behalf of consumers who were allegedly forced to pay higher prices for the antidepressant due to GlaxoSmithKline’s attempts to keep a generic form of the medication off the market.
The class action lawsuit over Wellbutrin was brought by the Health & Welfare Plan for the Sheet Metal Workers Local 441 in Mobile, Alabama, in the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs sought class action status on behalf of all individual consumers and more than 20,000 third-parties, such as health care plans and insurers.
The lawsuit claimed that Glaxo was attempting to delay the release of generic Wellbutrin versions through frivolous patent lawsuits against generic drug makers. Earlier this month, U.S. District Judge Lawrence F. Stengel declined to give the lawsuit class action status, saying that it would be impossible for plaintiffs to prove that the class members were financially injured by Glaxo’s actions.
Stengel determined that it would be impossible to determine which customers would have exhibited brand loyalty to GlaxoSmithKline, meaning that they would continue to buy brand-name Wellbutrin even after generic versions were released. Without being able to determine who would buy generic versions and who would not, the plaintiffs do not have a class action case, he ruled.
Wellbutrin (bupropion HCI), which is manufactured by GlaxoSmithKline, was first approved by FDA as an antidepressant in December 1985. The drug was pulled a year later due to the high number of seizures associated with Wellbutrin side effects, but it was reintroduced in 1989 after federal reviewers determined that the seizures were dose specific and lowered the daily dosage of the drug.
Wellbutrin has come under closer scrutiny recently after a study published in May in the American Journal of Obstetrics & Gynecology suggested that there may be an increased risk of heart birth defects from Wellbutrin when the medication is taken during pregnancy.
Researchers found that mothers who were given Wellbutrin in their first trimester had double the chance of giving birth to a child with a congenital heart problem than mothers who did not take the drug. However, they were not able to establish a cause-and-effect relationship between the drug and the birth defects.
Published: October 26th, 2010 • No Comments
http://www.aboutlawsuits.com/wellbutrin-class-action-lawsuit-denied-13699/
A federal judge has refused to grant certification for a Wellbutrin class action lawsuit filed on behalf of consumers who were allegedly forced to pay higher prices for the antidepressant due to GlaxoSmithKline’s attempts to keep a generic form of the medication off the market.
The class action lawsuit over Wellbutrin was brought by the Health & Welfare Plan for the Sheet Metal Workers Local 441 in Mobile, Alabama, in the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs sought class action status on behalf of all individual consumers and more than 20,000 third-parties, such as health care plans and insurers.
The lawsuit claimed that Glaxo was attempting to delay the release of generic Wellbutrin versions through frivolous patent lawsuits against generic drug makers. Earlier this month, U.S. District Judge Lawrence F. Stengel declined to give the lawsuit class action status, saying that it would be impossible for plaintiffs to prove that the class members were financially injured by Glaxo’s actions.
Stengel determined that it would be impossible to determine which customers would have exhibited brand loyalty to GlaxoSmithKline, meaning that they would continue to buy brand-name Wellbutrin even after generic versions were released. Without being able to determine who would buy generic versions and who would not, the plaintiffs do not have a class action case, he ruled.
Wellbutrin (bupropion HCI), which is manufactured by GlaxoSmithKline, was first approved by FDA as an antidepressant in December 1985. The drug was pulled a year later due to the high number of seizures associated with Wellbutrin side effects, but it was reintroduced in 1989 after federal reviewers determined that the seizures were dose specific and lowered the daily dosage of the drug.
Wellbutrin has come under closer scrutiny recently after a study published in May in the American Journal of Obstetrics & Gynecology suggested that there may be an increased risk of heart birth defects from Wellbutrin when the medication is taken during pregnancy.
Researchers found that mothers who were given Wellbutrin in their first trimester had double the chance of giving birth to a child with a congenital heart problem than mothers who did not take the drug. However, they were not able to establish a cause-and-effect relationship between the drug and the birth defects.
Paxil birth defect mother became pregnant late in life - child plays volleyball and takes tae kwon do lessons
Glaxo officials contend Paxil played no role in Anna’s heart defects. They were most likely caused by genetics or the fact that her mother became pregnant late in life, Chilton Varner, a lawyer for the drugmaker, told jurors.
The deaths of Paxil animal test subjects had nothing “to do with Anna Blyth’s heart defects,” Varner said.
http://www.bloomberg.com/news/2010-11-09/glaxo-failed-to-warn-about-paxil-risks-lawyer-says-at-philadelphia-trial.html
Varner also said Anna, an honor student who plays volleyball and takes tae kwon do lessons, has suffered no lasting effects from her early heart problems.
“She is not on any heart medications and hasn’t suffered any palpitations,” Varner said. “That’s the good news in the case.”
The deaths of Paxil animal test subjects had nothing “to do with Anna Blyth’s heart defects,” Varner said.
http://www.bloomberg.com/news/2010-11-09/glaxo-failed-to-warn-about-paxil-risks-lawyer-says-at-philadelphia-trial.html
Varner also said Anna, an honor student who plays volleyball and takes tae kwon do lessons, has suffered no lasting effects from her early heart problems.
“She is not on any heart medications and hasn’t suffered any palpitations,” Varner said. “That’s the good news in the case.”
Tuesday, 9 November 2010
Baum Hedlund - Paxil / Seroxat's Donald Schell was depressed
extract
'Three-Legged Stool'
There was no question that Donald Schell was depressed. Before taking Paxil, he had been on other antidepressants including Prozac.
Furthermore, there seemed to be no other motivation for the murder-suicide. He had no obvious marital problems and clearly adored his daughter and granddaughter. So the pivotal question of the trial was: Did taking Paxil for two days - one pill each day - cause Schell to go berserk? Or did he become violent because he was already depressed?
This chicken-and-egg-type question had been at the heart of other the other antidepressant trials, as Vickery knew well. He had tried and lost a similar case - Forsyth v. Eli Lilly & Co. - in Hawaii in 1999.
"In Hawaii, I stupidly [bought into their] either/or argument: Was it the drug or the depression? Here I just focused on the drug." By doing so, he reframed the debate for the jury from, "Was it the depression or the drug?" to "Is it possible for the drug to produce a violent reaction in some people?"
http://www.baumhedlundlaw.com/media/ssri/Paxil_murder.htm
'Three-Legged Stool'
There was no question that Donald Schell was depressed. Before taking Paxil, he had been on other antidepressants including Prozac.
Furthermore, there seemed to be no other motivation for the murder-suicide. He had no obvious marital problems and clearly adored his daughter and granddaughter. So the pivotal question of the trial was: Did taking Paxil for two days - one pill each day - cause Schell to go berserk? Or did he become violent because he was already depressed?
This chicken-and-egg-type question had been at the heart of other the other antidepressant trials, as Vickery knew well. He had tried and lost a similar case - Forsyth v. Eli Lilly & Co. - in Hawaii in 1999.
"In Hawaii, I stupidly [bought into their] either/or argument: Was it the drug or the depression? Here I just focused on the drug." By doing so, he reframed the debate for the jury from, "Was it the depression or the drug?" to "Is it possible for the drug to produce a violent reaction in some people?"
http://www.baumhedlundlaw.com/media/ssri/Paxil_murder.htm
The Evidence, However, Is Clear - only 102 votes in entire year
Sarah Venn barrister in breech of Seroxat group finance rules !
Finance
1.The funds of the Group, including all donations, contributions and bequests, shall be paid into an account operated by the Committee in the name of the Group at such bank as the Committee shall decide.
2.Group funds must only be spent in furtherance of the objects and activities ancillary to the objects.
3.At least two committee members will be authorised signatories of the bank account, one of which must be the Treasurer.
4.No committee member must withdraw funds from the bank account unless there are cleared funds to cover the withdrawal.
http://www.seroxatusergroup.org.uk/Documents/rulesgroup.doc
1.The funds of the Group, including all donations, contributions and bequests, shall be paid into an account operated by the Committee in the name of the Group at such bank as the Committee shall decide.
2.Group funds must only be spent in furtherance of the objects and activities ancillary to the objects.
3.At least two committee members will be authorised signatories of the bank account, one of which must be the Treasurer.
4.No committee member must withdraw funds from the bank account unless there are cleared funds to cover the withdrawal.
http://www.seroxatusergroup.org.uk/Documents/rulesgroup.doc
Monday, 8 November 2010
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and others [2008] EWCA Civ 1086; [2008] WLR (D) 317
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and others [2008] EWCA Civ 1086; [2008] WLR (D) 317
CA: Tuckey, Arden and Longmore LJJ: 14 October 2008
http://www.lawreports.co.uk/WLRD/2008/CACiv/oct0.5.htm
--------------------------------------------------------------------------------
CA: Tuckey, Arden and Longmore LJJ: 14 October 2008
http://www.lawreports.co.uk/WLRD/2008/CACiv/oct0.5.htm
--------------------------------------------------------------------------------
Irwin Mitchell loses vitamins appeal - Class action lobby dealt body blow
Irwin Mitchell suffered a blow in the Court of Appeal last week in a case that could spell the end for US-style class actions in the UK.
http://www.thelawyer.com/class-action-lobby-dealt-body-blow-as-irwin-mitchell-loses-vitamins-appeal/135288.article
In ;2004 ;the ;firm embarked on a mission to bring the first multi-party action for damages. The case was brought against a series of vitamins companies, including Switzerland’s Hoffman-La Roche and Germany-based BASF, which had been on the receiving end of an e855m (£669.94m) fine after being found guilty of colluding on price-fixing.
Irwin ;Mitchell ;was brought ;on ;board ;to represent a number of clients from the poultry and animal feeds sector, which alleged that the activities of the companies unfairly inflated the prices they were paying for vitamins.
.The ;lead ;claimant, Devenish Nutrition, a Belfast-based supplier of pig and poultry feed, was seeking a share of the cartelists’ profits, despite being unable to prove that it had made a financial loss as a result of the cartel.
The Court of Appeal was asked to determine whether the claimants were entitled to compensatory damages, exemplary ;damages, restitutionary damages and an account of profits.
Irwin Mitchell instructed Christopher Vajda QC of Monckton Chambers and Andrew Burrows QC of Atkin Chambers to argue that compensatory damages alone would not be an adequate remedy.
The claimants argued that, if the court ruled in their favour, it would act as a deterrent against other cartelists.
In an ideal world the case would have been brought in the US, where claims such as these are seen as the key deterrent in preventing cartels from being established.
However, here in the UK, where class actions are still unusual, Irwin Mitchell was forced to go to the Court of Appeal after the claim was rejected by the High Court.
The Court of Appeal’s 14 October decision could be another nail in the coffin for the class action lobby in the UK. For several years it has been pushing for a change in UK law to allow more people to participate in class actions.
“It’s certainly the end of people trying it on,” said one senior partner close to the case. “These people seem to be encouraged by lawyers who want them to get damages for losses they haven’t suffered. This is a sensible ruling which sits within the law as it is. The judges couldn’t have done anything else.”
According to Cohen Milstein Hausfeld & Toll partner Vincent Smith, the Devenish litigation is a good example of how cases can collapse if collective claimants ;fail ;to ;act together.
Smith said: “This wasn’t an unexpected ruling – [the judges] are bound by previous precedent. What it does show is that we need to choose claimants very carefully and make sure everybody’s involved from the very beginning.”
Smith said the case highlighted an urgent need for a framework on which to bring class actions.
“The Government is expected to respond to the CJC recommendations on class actions shortly and we expect it to come out in favour of the proposals,” he added.
To some extent the ruling recognises that changes are afoot in the class action arena. Yet Mr Justice Longmore pointed out that the court cannot act alone.
Longmore J, who sat alongside Mr Justice Tuckey and Lady Justice Arden, said: “The only real argument in favour of an order for an account of profits is the argument of policy that cartels are a notorious evil and the civil courts should in some way provide an incentive for their eradication by making such an order.
“But it doesn’t seem to me to be right for the courts to take this step on their own initiative.
“Neither the law of restitution nor the law of damages is in the business of transferring monetary gains from one undeserving recipient to another undeserving recipient, even if the former has acted illegally while the latter has not.”
With this single sentence, Longmore J must have shaken the confidence of every claimant lawyer looking to bring a class action.
“I think the class action lobby are on a hiding to nothing in the UK court,” said one litigation partner. “These are claimants who’ve suffered no actual loss – why should they be entitled to damages?”
But Irwin Mitchell’s lead partner on the case Jeremy Marshall is now planning to seek leave to appeal to the House of Lords. “This isn’t yet over, and the Court of Appeal’s given us the inkling that this should go to the Law Lords,” Marshall said.
It is understood that Irwin Mitchell is working on a contingency fee basis and therefore has a lot riding on the success of this case. If the firm wins in the Lords it will certainly be able to say that it won against the odds.
Claimant lawyers have for some time been calling on the Government to improve access to justice by modifying the class action framework and allowing more people to participate. Yet at every corner the lobby is curtailed by current UK case law. Only the case against the BA-Virgin cartel has been successful and that was largely because it was first brought in the US.
And while the defendant has the cash to pay for powerful lawyers and the claimant still scratches around for suitable funding, the situation will remain.
http://www.thelawyer.com/class-action-lobby-dealt-body-blow-as-irwin-mitchell-loses-vitamins-appeal/135288.article
In ;2004 ;the ;firm embarked on a mission to bring the first multi-party action for damages. The case was brought against a series of vitamins companies, including Switzerland’s Hoffman-La Roche and Germany-based BASF, which had been on the receiving end of an e855m (£669.94m) fine after being found guilty of colluding on price-fixing.
Irwin ;Mitchell ;was brought ;on ;board ;to represent a number of clients from the poultry and animal feeds sector, which alleged that the activities of the companies unfairly inflated the prices they were paying for vitamins.
.The ;lead ;claimant, Devenish Nutrition, a Belfast-based supplier of pig and poultry feed, was seeking a share of the cartelists’ profits, despite being unable to prove that it had made a financial loss as a result of the cartel.
The Court of Appeal was asked to determine whether the claimants were entitled to compensatory damages, exemplary ;damages, restitutionary damages and an account of profits.
Irwin Mitchell instructed Christopher Vajda QC of Monckton Chambers and Andrew Burrows QC of Atkin Chambers to argue that compensatory damages alone would not be an adequate remedy.
The claimants argued that, if the court ruled in their favour, it would act as a deterrent against other cartelists.
In an ideal world the case would have been brought in the US, where claims such as these are seen as the key deterrent in preventing cartels from being established.
However, here in the UK, where class actions are still unusual, Irwin Mitchell was forced to go to the Court of Appeal after the claim was rejected by the High Court.
The Court of Appeal’s 14 October decision could be another nail in the coffin for the class action lobby in the UK. For several years it has been pushing for a change in UK law to allow more people to participate in class actions.
“It’s certainly the end of people trying it on,” said one senior partner close to the case. “These people seem to be encouraged by lawyers who want them to get damages for losses they haven’t suffered. This is a sensible ruling which sits within the law as it is. The judges couldn’t have done anything else.”
According to Cohen Milstein Hausfeld & Toll partner Vincent Smith, the Devenish litigation is a good example of how cases can collapse if collective claimants ;fail ;to ;act together.
Smith said: “This wasn’t an unexpected ruling – [the judges] are bound by previous precedent. What it does show is that we need to choose claimants very carefully and make sure everybody’s involved from the very beginning.”
Smith said the case highlighted an urgent need for a framework on which to bring class actions.
“The Government is expected to respond to the CJC recommendations on class actions shortly and we expect it to come out in favour of the proposals,” he added.
To some extent the ruling recognises that changes are afoot in the class action arena. Yet Mr Justice Longmore pointed out that the court cannot act alone.
Longmore J, who sat alongside Mr Justice Tuckey and Lady Justice Arden, said: “The only real argument in favour of an order for an account of profits is the argument of policy that cartels are a notorious evil and the civil courts should in some way provide an incentive for their eradication by making such an order.
“But it doesn’t seem to me to be right for the courts to take this step on their own initiative.
“Neither the law of restitution nor the law of damages is in the business of transferring monetary gains from one undeserving recipient to another undeserving recipient, even if the former has acted illegally while the latter has not.”
With this single sentence, Longmore J must have shaken the confidence of every claimant lawyer looking to bring a class action.
“I think the class action lobby are on a hiding to nothing in the UK court,” said one litigation partner. “These are claimants who’ve suffered no actual loss – why should they be entitled to damages?”
But Irwin Mitchell’s lead partner on the case Jeremy Marshall is now planning to seek leave to appeal to the House of Lords. “This isn’t yet over, and the Court of Appeal’s given us the inkling that this should go to the Law Lords,” Marshall said.
It is understood that Irwin Mitchell is working on a contingency fee basis and therefore has a lot riding on the success of this case. If the firm wins in the Lords it will certainly be able to say that it won against the odds.
Claimant lawyers have for some time been calling on the Government to improve access to justice by modifying the class action framework and allowing more people to participate. Yet at every corner the lobby is curtailed by current UK case law. Only the case against the BA-Virgin cartel has been successful and that was largely because it was first brought in the US.
And while the defendant has the cash to pay for powerful lawyers and the claimant still scratches around for suitable funding, the situation will remain.
Legal aid removed in epilepsy case - source IBB Solicitors blog
Legal aid removed in epilepsy case
08th November 2010
http://www.ibblaw.co.uk/blog/519/legal-aid-removed-in-epilepsy-case
The Legal Services Commission (LSC) has withdrawn legal aid for a group of families suing the maker of a drug used to prevent epileptic seizures.
The LSC said it was no longer funding an action for damages against Sanofi-aventis, manufacturer of sodium valproate, which the familes claim caused birth defects in children.
About 80 families claim the drug, also known as epilim, caused a range of defects including spina bifida, heart damage, learning difficulties, cleft palate and deformities of the hands and feet.
The claimants said there were inadequate warnings about possible harm from the drug in the 1990s, but the firm has denied the allegation, saying it has always provided appropriate warnings on the risks associated with possible side-effects.
Dr Ian Weatherhead, communications director for sanofi-aventis, said: “We have sympathy for the claimants but we have always believed that their case would be unsuccessful.”
A spokesman for the LSC said: “Legal aid is no longer funding an action against the makers of the drug epilim. However, because proceedings are still ongoing we are unable to comment further.”
IBB Solicitors has built a reputation for quality of service in pursuing compensation in cases involving accident, illness or death. If you would like advice on personal injury issues, you can contact a member of IBB’s Personal Injury team, call us on 08456 381 381 or email enquiries@ibblaw.co.uk.
08th November 2010
http://www.ibblaw.co.uk/blog/519/legal-aid-removed-in-epilepsy-case
The Legal Services Commission (LSC) has withdrawn legal aid for a group of families suing the maker of a drug used to prevent epileptic seizures.
The LSC said it was no longer funding an action for damages against Sanofi-aventis, manufacturer of sodium valproate, which the familes claim caused birth defects in children.
About 80 families claim the drug, also known as epilim, caused a range of defects including spina bifida, heart damage, learning difficulties, cleft palate and deformities of the hands and feet.
The claimants said there were inadequate warnings about possible harm from the drug in the 1990s, but the firm has denied the allegation, saying it has always provided appropriate warnings on the risks associated with possible side-effects.
Dr Ian Weatherhead, communications director for sanofi-aventis, said: “We have sympathy for the claimants but we have always believed that their case would be unsuccessful.”
A spokesman for the LSC said: “Legal aid is no longer funding an action against the makers of the drug epilim. However, because proceedings are still ongoing we are unable to comment further.”
IBB Solicitors has built a reputation for quality of service in pursuing compensation in cases involving accident, illness or death. If you would like advice on personal injury issues, you can contact a member of IBB’s Personal Injury team, call us on 08456 381 381 or email enquiries@ibblaw.co.uk.
Epilim - Pregnancy and lactation warning - Summary of Product Characteristics
http://www.medicines.org.uk/EMC/medicine/6781/SPC/Epilim+500+Enteric+Coated/
4.6 Pregnancy and lactation
Women of childbearing potential should not be started on Epilim without specialist neurological advice.
Adequate counselling should be made available to all women with epilepsy of childbearing potential regarding the risks associated with pregnancy because of the potential teratogenic risk to the foetus (See also section 4.6.1).Women who are taking Epilim and who may become pregnant should receive specialist neurological advice and the benefits of its use should be weighed against the risks.
Epilim is the antiepileptic of choice in patients with certain types of epilepsy such as generalised epilepsy ± myoclonus/photosensitivity. For partial epilepsy, Epilim should be used only in patients resistant to other treatment.
If pregnancy is planned, consideration should be given to cessation of Epilim treatment, if appropriate.
When Epilim treatment is deemed necessary, precautions to minimize the potential teratogenic risk should be followed. (See also section 4.6.1 paragraph entitled “In view of the above”)
4.6.1 Pregnancy
- Risk associated with epilepsy and antiepileptics
In offspring born to mothers with epilepsy receiving any anti-epileptic treatment, the overall rate of malformations has been demonstrated to be higher than the rate (approximately 3 %) reported in the general population. An increased number of children with malformations have been reported in cases of multiple drug therapy. Malformations most frequently encountered are cleft lip and cardio-vascular malformations.
No sudden discontinuation in the anti-epileptic therapy should be undertaken as this may lead to breakthrough seizures which could have serious consequences for both the mother and the foetus.
Antiepileptic drugs should be withdrawn under specialist supervision.
- Risk associated with seizures
During pregnancy, maternal tonic clonic seizures and status epilepticus with hypoxia carry a particular risk of death for mother and the unborn child.
- Risk associated with valproate
In animals: teratogenic effects have been demonstrated in the mouse, rat and rabbit.
There is animal experimental evidence that high plasma peak levels and the size of an individual dose are associated with neural tube defects.
In humans: Available data suggest an increased incidence of minor or major malformations including neural tube defects, cranio-facial defects, malformations of the limbs, cardiovascular malformations, hypospadias and multiple anomalies involving various body systems in offspring born to mothers with epilepsy treated with valproate. The data suggest that the use of valproate is associated with a greater risk of certain types of these malformations (in particular neural tube defects) than some other anti-epileptic drugs.
Both valproate monotherapy and valproate as part of polytherapy are associated with abnormal pregnancy outcome. Available data suggest that antiepileptic polytherapy including sodium valproate is associated with a higher risk of abnormal pregnancy outcome than sodium valproate monotherapy.
Data have suggested an association between in-utero exposure to valproate and the risk of developmental delay (frequently associated with dysmorphic features), particularly of verbal IQ. However, the interpretation of the observed findings in offspring born to mothers with epilepsy treated with sodium valproate remains uncertain, in the view of possible confounding factors such as low maternal IQ, genetic, social, environmental factors and poor maternal seizure control during pregnancy.
Autism spectrum disorders have also been reported in children exposed to valproate in utero.
- In view of the above data
When a woman is planning pregnancy, this provides an opportunity to review the need for anti-epileptic treatment. Women of child-bearing potential should be informed of the risks and benefits of the use of Epilim during pregnancy. Specialist advice is required and physicians are strongly encouraged to discuss reproductive issues with their patients before Epilim is prescribed for the first time or a woman already treated with Epilim is planning a pregnancy.
Folate supplementation, prior to pregnancy, has been demonstrated to reduce the incidence of neural tube defects in the offspring of women at high risk. Although no direct evidence exists of such effects in women receiving anti-epileptic drugs, women should be advised to start taking folic acid supplementation (5mg) as soon as contraception is discontinued.
The available evidence suggests that anticonvulsant monotherapy is preferred. Dosage should be reviewed before conception and the lowest effective dose used, in divided doses, as abnormal pregnancy outcome tends to be associated with higher total daily dosage and with the size of an individual dose. The incidence of neural tube defects rises with increasing dosage, particularly above 1000mg daily. The administration in several divided doses over the day and the use of a prolonged release formulation is preferable in order to avoid high peak plasma levels.
During pregnancy, Epilim anti-epileptic treatment should not be discontinued without reassessment of the benefit/risk.
Nevertheless, specialised prenatal monitoring should be instituted in order to detect the possible occurrence of a neural tube defect or any other malformation. Pregnancies should be carefully screened by ultrasound, and other techniques if appropriate (see Section 4.4 Special Warnings and Precautions for use).
- Risk in the neonate
Very rare cases of haemorrhagic syndrome have been reported in neonates whose mothers have taken Epilim during pregnancy. This haemorrhagic syndrome is related to hypofibrinogenemia; afibrinogenemia has also been reported and may be fatal. These are possibly associated with a decrease of coagulation factors. However, this syndrome has to be distinguished from the decrease of the vitamin-K factors induced by phenobarbital and other anti-epileptic enzyme inducing drugs.
Therefore, platelet count, fibrinogen plasma level, coagulation tests and coagulation factors should be investigated in neonates.
4.6.2 Lactation
Excretion of Epilim in breast milk is low, with a concentration between 1 % to 10 % of total maternal serum levels. Although there appears to be no contra-indication to breastfeeding, physicians are advised that in any individual case, consideration should be given to the safety profile of Epilim, specifically haematological disorders (see section 4.8 Undesirable Effects).
4.6 Pregnancy and lactation
Women of childbearing potential should not be started on Epilim without specialist neurological advice.
Adequate counselling should be made available to all women with epilepsy of childbearing potential regarding the risks associated with pregnancy because of the potential teratogenic risk to the foetus (See also section 4.6.1).Women who are taking Epilim and who may become pregnant should receive specialist neurological advice and the benefits of its use should be weighed against the risks.
Epilim is the antiepileptic of choice in patients with certain types of epilepsy such as generalised epilepsy ± myoclonus/photosensitivity. For partial epilepsy, Epilim should be used only in patients resistant to other treatment.
If pregnancy is planned, consideration should be given to cessation of Epilim treatment, if appropriate.
When Epilim treatment is deemed necessary, precautions to minimize the potential teratogenic risk should be followed. (See also section 4.6.1 paragraph entitled “In view of the above”)
4.6.1 Pregnancy
- Risk associated with epilepsy and antiepileptics
In offspring born to mothers with epilepsy receiving any anti-epileptic treatment, the overall rate of malformations has been demonstrated to be higher than the rate (approximately 3 %) reported in the general population. An increased number of children with malformations have been reported in cases of multiple drug therapy. Malformations most frequently encountered are cleft lip and cardio-vascular malformations.
No sudden discontinuation in the anti-epileptic therapy should be undertaken as this may lead to breakthrough seizures which could have serious consequences for both the mother and the foetus.
Antiepileptic drugs should be withdrawn under specialist supervision.
- Risk associated with seizures
During pregnancy, maternal tonic clonic seizures and status epilepticus with hypoxia carry a particular risk of death for mother and the unborn child.
- Risk associated with valproate
In animals: teratogenic effects have been demonstrated in the mouse, rat and rabbit.
There is animal experimental evidence that high plasma peak levels and the size of an individual dose are associated with neural tube defects.
In humans: Available data suggest an increased incidence of minor or major malformations including neural tube defects, cranio-facial defects, malformations of the limbs, cardiovascular malformations, hypospadias and multiple anomalies involving various body systems in offspring born to mothers with epilepsy treated with valproate. The data suggest that the use of valproate is associated with a greater risk of certain types of these malformations (in particular neural tube defects) than some other anti-epileptic drugs.
Both valproate monotherapy and valproate as part of polytherapy are associated with abnormal pregnancy outcome. Available data suggest that antiepileptic polytherapy including sodium valproate is associated with a higher risk of abnormal pregnancy outcome than sodium valproate monotherapy.
Data have suggested an association between in-utero exposure to valproate and the risk of developmental delay (frequently associated with dysmorphic features), particularly of verbal IQ. However, the interpretation of the observed findings in offspring born to mothers with epilepsy treated with sodium valproate remains uncertain, in the view of possible confounding factors such as low maternal IQ, genetic, social, environmental factors and poor maternal seizure control during pregnancy.
Autism spectrum disorders have also been reported in children exposed to valproate in utero.
- In view of the above data
When a woman is planning pregnancy, this provides an opportunity to review the need for anti-epileptic treatment. Women of child-bearing potential should be informed of the risks and benefits of the use of Epilim during pregnancy. Specialist advice is required and physicians are strongly encouraged to discuss reproductive issues with their patients before Epilim is prescribed for the first time or a woman already treated with Epilim is planning a pregnancy.
Folate supplementation, prior to pregnancy, has been demonstrated to reduce the incidence of neural tube defects in the offspring of women at high risk. Although no direct evidence exists of such effects in women receiving anti-epileptic drugs, women should be advised to start taking folic acid supplementation (5mg) as soon as contraception is discontinued.
The available evidence suggests that anticonvulsant monotherapy is preferred. Dosage should be reviewed before conception and the lowest effective dose used, in divided doses, as abnormal pregnancy outcome tends to be associated with higher total daily dosage and with the size of an individual dose. The incidence of neural tube defects rises with increasing dosage, particularly above 1000mg daily. The administration in several divided doses over the day and the use of a prolonged release formulation is preferable in order to avoid high peak plasma levels.
During pregnancy, Epilim anti-epileptic treatment should not be discontinued without reassessment of the benefit/risk.
Nevertheless, specialised prenatal monitoring should be instituted in order to detect the possible occurrence of a neural tube defect or any other malformation. Pregnancies should be carefully screened by ultrasound, and other techniques if appropriate (see Section 4.4 Special Warnings and Precautions for use).
- Risk in the neonate
Very rare cases of haemorrhagic syndrome have been reported in neonates whose mothers have taken Epilim during pregnancy. This haemorrhagic syndrome is related to hypofibrinogenemia; afibrinogenemia has also been reported and may be fatal. These are possibly associated with a decrease of coagulation factors. However, this syndrome has to be distinguished from the decrease of the vitamin-K factors induced by phenobarbital and other anti-epileptic enzyme inducing drugs.
Therefore, platelet count, fibrinogen plasma level, coagulation tests and coagulation factors should be investigated in neonates.
4.6.2 Lactation
Excretion of Epilim in breast milk is low, with a concentration between 1 % to 10 % of total maternal serum levels. Although there appears to be no contra-indication to breastfeeding, physicians are advised that in any individual case, consideration should be given to the safety profile of Epilim, specifically haematological disorders (see section 4.8 Undesirable Effects).
Subscribe to:
Posts (Atom)





